Inclusion Criteria:

- Signed Informed Consent Form

- Age ≥ 18 years

- Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred

- No prior chemotherapy in the recurrent setting

- Measurable disease

- Recovered from prior radiation therapy or surgery

Exclusion Criteria:

- Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian
tube carcinoma

- History of abdominal fistula, gastrointestinal perforation (GIP), or intra-abdominal
abscess

- Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who
require parenteral hydration, parenteral nutrition, or tube feeding

- Patients with evidence of abdominal free air not explained by paracentesis or recent
surgical procedure

- Current, recent, or planned participation in an experimental drug study

- History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor
(VEGF) or VEGF receptor-targeted agent use

- Inadequately controlled hypertension

- Prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association Class II or greater congestive heart failure (CHF)

- History of myocardial infarction or unstable angina

- History of stroke or transient ischemic attack (TIA)

- Known central nervous system (CNS) disease except for treated brain metastasis

- Significant vascular disease or recent peripheral arterial thrombosis

- History of hemoptysis

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)